ACRS | Aclaris Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	3.67 - 4.44
52 Week Range	0.7700 - 4.44
Beta	-0.11
Implied Volatility	162.69%
IV Rank	38.31%
Day's Volume	5,737,712
Average Volume	1,050,287
Shares Outstanding	71,430,900
Market Cap	282,866,364
Sector	Healthcare
Industry	Medical - Diagnostics & Research
IPO Date	2015-10-06

Valuation
Profitability
Growth
Health
P/E Ratio	-7.62
Forward P/E Ratio	-4.57
EPS	-0.52
1YR Price Target	30.50
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	86
Country	USA
Website	ACRS

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.

ACRS's peers: NEOG, QGEN, OLK, SYNH, SHC, RDNT, MYGN, GTH, BDSX, CSTL, PRE, IQV, MEDP, ICLR, CHEK, NEO, TRIB, RVTY

*Chart delayed

Analyzing fundamentals for ACRS we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see ACRS Fundamentals page.

Watching at ACRS technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, but short-term trend is bullish. More technicals details can be found on ACRS Technicals page.